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1. Introduction 
The relationship between sex hormones and cardiovascular function and disease has long 
been recognized. As early as the 1950s, researchers concluded that although levels of 
cholesterol played a major role in the development of cardiovascular disease (CVD), other 
factors, including gender and hormones, played a role as well. (Anonymous, 1958). Since 
that time, despite extensive research focusing on the effects of estrogen on vascular function, 
the relationship remains poorly understood. Furthermore, clinical treatment of 
postmenopausal women with hormone replacement therapy (HRT) continues to be 
controversial due to conflicting findings in clinical trials. 
Until the 1990s, extensive observational data suggested that HRT was cardioprotective. 
However, results from the Heart and Estrogen/Progestin Replacement Study (HERS-I and –
II) did not confirm a protective effect of HRT on the heart. (Hulley et al 1996; Grady et al 
2002). Later, data from the Women’s Health Initiative (WHI) reported an increase in 
coronary heart disease (CHD) risk in women treated with combined estrogen-progestin 
compared to placebo, while the WHI unopposed-estrogen arm showed no increase in CHD 
events (Roussow et al, 2002; Anderson et al, 2004). Since release of the WHI, follow-up 
analyses have shown that the timing of initiation of HRT makes a difference in outcomes. 
These analyses showed that younger postmenopausal women who initiate therapy at the 
time of menopause are not at increased risk of CHD events compared to women who 
initiate therapy at a later age. 
In this chapter, we will discuss the pathophysiologic effects of sex hormones on the 
vasculature, describe both clinical and basic research that has led us to our current 
understanding, and conclude with future perspectives on avenues of investigation that may 
lead to innovative treatments for postmenopausal women. 
2. Physiology of estrogen actions 
2.1 Estrogen metabolism 
Estrogen is a steroid hormone that is produced by aromatization of androgen precursors, 
specifically androstenedione. (Speroff and Fritz, 2005) Estrogens are synthesized primarily 
in the ovary, with minor contribution from adipose, skin, muscle, and endometrial tissue. In 
premenopausal women, the primary form of estrogen is 17ǃ-estradiol, often simply referred 
to as estradiol or E2 (for the two hydroxyl groups located on the basic estrogen ring 
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structure). (Speroff and Fritz, 2005)  Estradiol is the form of estrogen used in most pre-
clinical studies, and will be abbreviated as ‘E2’ in this chapter. Clinical studies, particularly 
studies of HRT, have employed a variety of naturally occurring or synthetic estrogens, 
which will be identified specifically in the text. Other forms of estrogen include estrone and 
estriol. Estrone, like estradiol, is produced by aromatization of androstenedione, and is the 
primary estrogen in postmenopausal women. Estriol is a peripheral metabolite of estrone 
and estradiol and is not secreted by the ovary. Estriol is the dominant form of estrogen in 
pregnant women. (Speroff and Fritz, 2005) 
 
 
Fig. 1. Estrogen Metabolism (modified from Science Slides Suite © 2010) 
The majority of circulating estrogens are bound to carrier proteins, including albumin and 
sex hormone-binding globulin (SHBG). Albumin binds 30 percent of circulating estrogen 
and SHBG binds another 69 percent. (Speroff and Fritz, 2005) Only the remaining 1 percent 
of estrogen that is not protein bound is physiologically active. 
2.2 Estrogen receptors 
Estrogens act on specific estrogen receptors (ERs) that are differentially expressed in various 
tissues. There are at least three, and possibly four distinct estrogen receptors.  Two of these 
are the classic ERs: ERǂ and ER-ǃ. Other ERs include the more recently discovered G 
protein-coupled receptor (GPER,  GPR30, and a putative receptor (ER-X), that has been 
studied mainly in brain. (Miller et al, 2008) 
ERǂ and ERǃ are members of the nuclear steroid hormone receptor superfamily and 
function as ligand-activated transcription factors. (Speroff and Fritz, 2005) They are 
expressed in the vasculature and play a role in mediating/modulating responses to vascular 
injury. Once an estrogen ligand binds to its receptor, the receptor undergoes a 
conformational change that leads to downstream events in the nucleus, activating or 
inactivating transcription factors that lead to alterations in gene expression. The 
conformational plasticity of the ERs is a major reason that estrogen is able to have a variety 
of agonist/antagonist effects in a given cell or tissue. (Speroff and Fritz, 2005)  ERǂ and ERǃ 
play a pivotal role in vascular remodeling in response to vascular injury.  
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GPER (GPR30) is an intracellular transmembrane ER that initiates many rapid non-genomic 
signaling events, including intracellular calcium mobilization and synthesis of 
phosphatidyl-inositol 3,4,5-triphosphate in the nucleus of multiple cell types. (Revankar et 
al, 2005). GPER has been indentified in human internal mammary arteries, saphenous veins, 
and contributes to vasorelaxation in arteries, although this mechanism remains to be fully 
understood (Haas et al, 2009) 
Estrogen acts on various cell types through both genomic and non–genomic mechanisms.  
Genomic effects occur when estrogen binds to ERs in target tissue cell nuclei, resulting in 
changes in gene expression. Multiple genes in both the nuclear and mitochondrial genomes 
are regulated by ERǂ and ER-ǃ. (O’Lone et al, 2007) In aortic smooth muscle cells and 
endothelial cells of wild-type ovariectomized mice, E2 treatment resulted in both up- and 
down-regulation of multiple genes involved in mitochondrial fuction. ERǂ upregulated four 
clusters of genes, while ERǃ downregulated a different set of mitochondrial genes. E2 also 
stimulates oxidative phosphorylation and inhibits production of superoxide and other 
reactive oxygen species in mitochondria. (O’Lone et al, 2007)  It is hypothesized that this 
mechanism decreases the rate of accumulation of mitochondrial DNA mutations over a 
lifespan, and therefore protects against age-related disease. This notion is relevant to the 
development of CVD and timing of HRT initiation. (O’Lone et al, 2007) 
Estrogen can also trigger non-genomic events by binding to targets other than nuclear 
receptors, eg., cell membrane ERs. (Kelly and Levin, 2001)  Non-genomic effects, such as 
direct activation of intracellular signaling pathways, can be rapid and do not require 
changes in gene expression, although the long-term consequences include altered 
transcription of targeted genes.  
3. Physiology of progesterone actions  
3.1 Progesterone metabolism and progesterone receptors 
Progesterone is a steroid hormone that is synthesized from the precursor pregnenolone (a 
cholesterol metabolite) by 3ǃ-hydroxysteroid dehydrogenase in the ovaries and adrenal 
glands. (Figure 2) 
 
 
Fig. 2. Progesterone Metabolism ((modified from Science Slides Suite © 2010)) 
Progesterone acts on two major progesterone receptors (PRs), PR-A and PR-B. (Speroff and 
Fritz, 2005)  While the role of ERs in vascular physiology and pathophysiology is well 
studied, the literature on PRs is limited and most of what is known about their biological 
function is derived from studies of reproductive tissues. PR-A and PR-B can form 
homodimers (AA and BB) or heterodimers (AB) upon binding to a progestin. Downstream 
effects include protein phosphorylation and modulation of gene transcription. (Speroff and 
Fritz, 2005) Based on in-vitro studies of endometrium and breast tissue, PR-B is a positive 
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regulator of progesterone-responsive genes, whereas PR-A activation inhibits PR-B activity. 
Like estrogen, progesterone has both genomic and non-genomic effects, binding both 
nuclear and cell membrane receptors. 
4. Physiologic effects of sex hormones on the vasculature 
4.1 Estrogen effects on vascular reactivity 
E2 has rapid non-genomic actions on the arterial wall, resulting in vasodilation. 
Administration of E2 to ovariectomized ewes results in rapid uterine vasodilation, leading 
to a rise in uterine blood flow within 30 to 45 min (Killam et al, 1973). This rise in uterine 
blood flow is partially mediated by ER activation and release of nitric oxide (NO), as shown 
by local infusion of the nonselective ER blocker ICI 182,780 or the NO synthase blocker L-
NAME, respectively, into the main uterine artery of nonpregnant ewes (Van Buren et al, 
1992) A better understanding of the mechanism(s) by which E2 increases NO production in 
the vasculature comes from in vitro experiments with cultured endothelial cells. E2 
stimulates eNOS activity via an ERǂ-mediated process in endothelial cells (Chen et al, 1999). 
ERǂ and ERǃ are present on the endothelial cell membrane and are expressed in a wide 
range of blood vessels from different vascular beds and species (Andersson et al, 2001). The 
ERǂ and eNOS proteins are organized into a functional signaling module in caveolae 
located on endothelial cell membranes (Chambliss et al, 2000). The role of the ERǃ in 
vasodilation is less clear, but studies from ERǃ knockout mice have shown an inhibitory role 
of ERǃ in ER-mediated NO relaxation (Petterson et al, 2000).  
GPER is a seven-transmembrane G protein-coupled ER that has only recently been shown to 
play a role in the vasculature (Haas et al, 2007). Isoflavones, natural estrogenic compounds 
(phytoestrogens) found in soy products, e.g. genistein and dadein, and selective ER 
modulators (SERMs), e.g. tamoxifen and raloxifene, bind to GPER (Filardo et al, 2000). 
Selective stimulation of GPER by intravenous infusion of the GPER agonist G-1 results in an 
acute reduction in blood pressure in rats (Haas et al, 2009). G-1 relaxes ex vivo rat and 
human arteries via an endothelium-dependent and L-NAME-sensitive mechanism (Haas et 
al, 2009). It is uncertain whether E2-induced relaxing responses are mediated via GPER or 
whether crosstalk between ER/ERǃ and GPER exists. Selective GPER antagonists like G-15 
(Dennis et al, 2009) might unravel a role for GPER-dependent vasorelaxation upon E2 
signaling in the vasculature. 
E2 results in vasorelaxation even in the absence of a functional endothelium (Jiang et al. 
1991), due primarily to Ca2+-antagonistic effects in smooth muscle cells. E2 inhibits 
voltage-dependent calcium inward currents on smooth muscle cells, but not on 
endothelial cells (Shan et al, 1994; Kitazawa et al, 1997). This leads to a reduction in 
intracellular Ca2+ concentration and lower Ca2+-calmodulin-dependent myosin light chain 
phosphorylation and contraction (Somlyo and Somlyo, 1994). In addition to these Ca2+-
antagonistic effects on smooth muscle cells, a variety of endothelium-independent 
mechanisms have been proposed to account for E2-induced vasodilation. E2 has been 
reported to increase cAMP and cGMP levels in the vasculature, thus suggesting a cyclic 
nucleotide-dependent mechanism of relaxation (Kuehl et al, 1974). For instance, in the 
porcine coronary artery, E2 causes relaxation via protein kinase G activation and cAMP-
dependent opening of large-conductance Ca2+-activated K+ channels (BKCa) (Rosenfeld et 
al, 2000). In human coronary artery smooth muscle cells, E2 has been shown to open BKCa 
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channels by stimulating neuronal NOS via a signal pathway involving PI3-kinase and Akt 
(Han et al, 2007).  
In summary, E2 at pharmacological concentrations causes vasorelaxation via a combination 
of endothelium-dependent, ER-mediated actions and contraction-modulating effects at the 
level of the smooth muscle cell. The E2-induced relaxing profile in a specific vascular bed 
depends on the species, gender, expression patterns and degree of dimerization and 
crosstalk between the ER subtypes.  
4.2 Sex hormone effects on blood pressure 
4.2.1 Estrogen effects on blood pressure 
Endogenous E2 lowers BP. Observational studies have demonstrated that BP is lower 
when E2 levels peak during the luteal phase than when they are at their nadir during the 
follicular phase of the menstrual cycle (Dunne et al, 1991; Karpanou et al, 1993; Chapman 
et al, 1997). Menopause is associated with a significant increase in BP in cross-sectional 
studies (Staessen et al, 1998). In a prospective study of BP in premenopausal, 
perimenopausal, and postmenopausal women, an age-independent 4-5 mmHg increase in 
systolic BP was found in postmenopausal women (Staessen et al, 1997). Further, BP is 
reduced when endogenous E2 levels are elevated during pregnancy (Siamopoulos et al, 
1996). Data on the BP effects of estrogen replacement therapy (ERT) in menopausal 
women have been inconsistent, with reports of BP neutral (PEPI Trial Writing Group, 
1995), BP lowering (Mercuro et al, 1997; Mercuro et al, 1998; Cagnacci et al, 1999; Seely et 
al, 1999; Butkevich et al, 2000) and BP elevating effects (Anderson et al, 2004; Wassertheil-
Smoller et al, 2000). In the Postmenopausal Estrogen/Progestin interventions (PEPI) trial, 
which enrolled 875 healthy normotensive early postmenopausal women, assignment to 
conjugated equine estrogens (CEE), 0.625 mg/d ± a progestin did not impact systolic or 
diastolic BP when compared with placebo controls (PEPI Trial Writing Group, 1995). In 
contrast, when transdermal E2 was administered at physiologic doses to healthy 
postmenopausal women in two studies that evaluated ambulatory BP, active treatment 
significantly lowered nocturnal systolic, diastolic and mean BP by 3-7 mmHg compared 
with placebo (Cagnacci et al, 1999; Seely et al, 1999). The observational study component 
of the WHI (WHI-OS) collected data on risk factors for CVD, including BP, from  
98,705 women aged 50-79 yr, the largest multiethnic, best characterized cohort of 
postmenopausal women ever studied (Wassertheil-Smoller et al, 2000). WHI-OS found 
that current HRT use was associated with a 25% greater likelihood of having hypertension 
compared with past use or no prior use. Further, among 5310 postmenopausal women 
randomized to CEE (0.625 mg/d) alone compared to a placebo group as part of the 
randomized controlled trial component of WHI, there was a 1.1-mmHg increase from 
baseline in systolic BP that persisted throughout the 6.8 yr of follow up (Anderson et al, 
2004). There was no difference in diastolic BP between treatment groups. 
4.2.2 Progestin effects on blood pressure 
Similar to estrogens, the effects of progestins on BP are dependent on the type of progestin. 
Natural progesterone has been associated with BP lowering or neutral effects. Higher levels 
of progesterone correlate with lower systolic but not diastolic BP during the second and 
third trimesters of pregnancy (Kristiansson et al, 2001). In a crossover study of 15 
postmenopausal women assigned to placebo or transdermal E2 ± intravaginal progesterone, 
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addition of progesterone did not affect the nocturnal BP lowering seen with E2 compared 
with placebo (Seely et al, 1999). Similarly, medroxyprogesterone acetate (MPA) appears to 
have BP neutral or lowering effects. In a double-blind, crossover study of postmenopausal 
women assigned to CEE and placebo or increasing doses of MPA, there was a dose-
dependent decrease in ambulatory daytime diastolic and mean BPs for women assigned to 
the progestin compared with placebo (Harvey et al, 2001). In contrast, most studies of 
synthetic progestins for contraception or hormone therapy have revealed a BP-elevating 
effect. Oral contraceptives in particular appear to precipitate or accelerate hypertension 
(Rosenthal et al, 2000). 
4.3 Estrogen effects on lipoproteins 
E2 also affects serum lipoprotein levels and the interaction of lipoproteins with cellular 
elements in the vessel wall. E2 has been shown to protect against atherosclerotic lesion 
formation in multiple animal models. In primate models, E2 results in up to a 66 percent 
decrease in aortic atherosclerotic plaque size. (Bjarnson et al, 1997) Mouse models have been 
widely used to study atherosclerosis because of the ability to easily inactivate targeted genes 
coding for apolipoprotein E (Apoe) and the LDL receptor (Ldlr) which lead to spontaneous 
development of atherosclerosis. E2 prevents both initiation and progression of 
atherosclerotic plaque development in these models. Using subcutaneous implanted E2-
releasing pellets to achieve physiologic serum levels, atherosclerotic plaques did not 
progress beyond the fatty streak stage in apolipoprotein E-deficient mice. (Elhage et al, 1997)  
Similarly, E2 has been shown to reduce atherosclerotic lesion size in male Apoe-/- mice. (Tse 
et al, 1999) Treatment of minimally-oxidized LDL with E2 leads to decreased cytotoxicity in 
cultured endothelial cells. (Negre-Salvayre et al, 1993)  E2 also inhibits LDL oxidation and 
decreases formation of cholesterol esters. (Huber et al, 1990)  
E2 effects on lipoproteins and atherosclerosis are mediated by both ER and ER. When E2-
treated mice that were deficient in ApoE alone were compared to mice that were deficient in 
both ApoE and ER, E2 reduced atherosclerotic plaque size in Apoe-/- mice by 80%. This 
effect was not seen in the Apoe-/- , ER-/- mice, indicating that ER plays a critical role in 
prevention of aterhosclerosis in this model. (Hodgin et al, 2001)   
Clinical studies have shown reductions in serum lipoproteins following oral estrogen 
replacement therapy. One study randomized women to treatment with CEE (Premarin 0.625 
mg) daily versus placebo. (Walsh et al, 1991)  The estrogen treatment group had a 15% 
reduction in serum concentrations of LDL cholesterol and a 16% increase in high density 
lipoprotein (HDL) cholesterol. Triglyceride levels increased by 24%. These results were 
consistent across the age spectrum; even women in their 8th decade of life showed similar 
changes in serum cholesterol levels. Oral estrogens facilitate postprandial clearance of 
atherogenic lipoproteins and increase serum HDL levels, specifically HDL2, which may play 
a major role in reduction of atherogenesis. Oral CEEs appear to increase HDL levels to a 
greater degree than oral E2. Triglyceride levels are increased with administration of both 
oral CEE and oral E2, though to a lesser extent by oral E2. 
Transdermal E2 formulations also decrease LDL levels, but to a lesser extent than oral 
preparations. (Stevenson et al 2009)  Transdermal estrogens have not been shown to alter 
postprandial lipoprotein clearance or circulating HDL levels, but may lower triglyceride 
levels. (Godsland et al, 2001)  
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4.4 Estrogen effects on C-reactive protein 
C-reactive protein (CRP) is an acute phase reactant that has been shown to be both a marker 
and a mediator of vascular disease. There is an E2-dependent sexual dimorphism in 
expression of human CRP in experimental models, i.e., the transgenic mouse expressing 
human CRP (CRPtg) (Szalai et al 1997, 1998, 2002) and in some human populations (Yamada 
et al, 2001). E2 treatment of male CRPtg can lower baseline CRP levels and removal of E2 
can restore its high baseline expression. (Szalai et al, 1998)  In postmenopausal women, oral 
CEE increases baseline CRP levels,  but low dose oral or transdermal E2 supplementation 
does not affect CRP. (Cushman et al, 1999; Vongpatanasin et al, 2003; Lakoski et al, 2005; 
Mosca et al, 2004)  This HRT-induced CRP increase occurs without a significant change in 
IL-6 or TNF-ǂ, major regulators of CRP under inflammatory conditions, suggesting that the 
effects of menopausal hormones on CRP do not reflect a generalized inflammatory state. 
(Vongpatanasin et al, 2003; Mosca et al, 2004)  Data from the WHI and the Women’s Health 
Study have demonstrated that CRP predicts CVD risk in post-menopausal women 
independent of HRT. (Kurtz et al, 2011)  HRT use had less predictive value than CRP levels 
in these studies. Thus, the clinical significance of hormone-related changes in circulating 
CRP levels remains uncertain.  
5. Estrogen effects on inflammation and vascular pathology 
5.1 Estrogen modulates pro-inflammatory mediator expression after vascular injury 
Inflammation plays a critical role in the pathogenesis of atherosclerosis and subsequent 
CVD. (Hansson et al, 2005) The process is initiated by activation of endothelial cells due to 
deposition of lipoproteins, pressure overload, and/or hyperglycemia, leading to increased 
expression of adhesion molecules (including selectin, vascular cell adhesion molecule 1 [ 
VCAM-1], and intercellular adhesion molecule 1 [ICAM-1]). These molecules cause 
circulating leukocytes to bind to vascular endothelial cells and release pro-inflammatory 
cytokines and growth factors. The bound leukocytes then infiltrate the vascular smooth 
muscle cells layer, leading to a cascade of cytokine secretion, further contributing to the local 
inflammatory environment within the vessel.  
Based on extensive studies using the rat carotid injury model, E2 has been shown to be a 
negative modulator of injury-induced vascular inflammation and neointima formation. 
(Bakir et al, 2000; Miller et al, 2004; Xing et al, 2004)   There is a sexual dimorphism in the 
response to vascular injury, with males demonstrating increased neointima formation 
compared to females. (Chen et al 1996, 1998; Levine et al 1996; Miller et al, 2004)  This sexual 
dimorphism is E2-dependent, based on evidence that physiologic levels of circulating E2 
(40-60 pg/ml) decrease neointima formation in both male and female gonadectomized 
animals. Furthermore, addition of MPA, the progestin used in the Women’s Health 
Initiative, opposes the effects of E2 on injury-induced vascular inflammation and neointima 
formation. (Levine et al, 1996)   
E2 modulates the vascular response to injury by reducing local expression of inflammatory 
mediators and influx of leukocytes into balloon-injured carotid arteries of ovariectomized 
rats. (Miller et al, 2004; Xing et al, 2004)  In particular, E2 decreases expression of cytokine-
induced neutrophil chemoattractant (CINC-2ǃ), a chemoattractant for neutrophils and 
monocyte chemoattractant protein (MCP-1) in injured arteries. (Xing et al, 2004)  This results 
in significant reductions in influx of these inflammatory leukocyte subtypes, limiting the 
injury response. (Figure 3) 
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Fig. 3. E2 effects on the early vascular injury response. (Adapted from Xing et al, 2009) 
5.2 The role of C-reactive protein in E2 modulation of vascular inflammation 
E2 also exerts an anti-inflammatory and vasoprotective effect in injured arteries of CRP 
transgenic (CRPtg) mice. CRPtg mice carry a transgene containing the entire human CRP 
gene and its promoters while the mouse supplies all the required trans-acting factors. (Hage 
et al, 2008) Since in CRPtg mice, human CRP increases several hundred-fold during an acute 
phase response, analogous to the human condition, this model is convenient for the in vivo 
study of the biologic activities, including vascular effects, of human CRP. Using CRPtg mice, 
we and others have established that human CRP is a pathogenic mediator of cardiovascular 
disease. (Danenberg et al, 2003; Paul et al, 2004; Zhang et al, 2010; Nagai et al, 2011; 
Takahashi et al, 2010)  
Using the carotid ligation model of acute vascular injury, we showed that young 
ovariectomized CRPtg  mice develop twofold greater neointima formation than control non 
transgenic (NTG) mice and that there are extensive deposits of human CRP in the neointima 
of injured vessels of these animals in the absence of an increase in blood levels of the 
protein. (Kumar et al, 1997; Hage et al, 2010; Wang et al, 2005; Xing et al, 2008)  These 
findings suggest that local expression of human CRP may exacerbate the adverse 
remodeling seen after acute arterial injury in the CRPtg model. To test the hypothesis that 
E2 can inhibit the vascular injury response attributed to human CRP, we treated 
ovariectomized CRPtg and control NTG mice with E2 prior to carotid ligation and observed 
that E2-treated CRPtg mice had a significant, ~85%, reduction in neointima formation 
compared to vehicle-treated CRPtg mice. The E2 effect was directionally similar but somewhat 
smaller in magnitude in control NTG mice. (Wang et al, 2005)  Since the exaggerated vascular 
injury response in CRPtg mice is mediated by immunoglobulin G Fc receptors  (FcRs) on 
macrophages, (Xing et al, 2008) and since E2, via its interaction with ERs, can reduce 
inflammatory cytokine release from activated human macrophages by decreasing expression 
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of the excitatory FcRs on these cells, (Kramer et al, 2004, 2007) it is plausible that the 
vasoprotective effects of E2 against CRP-mediated vascular injury response in female mice are 
regulated by its modulation of macrophage phenotype in order to express less activating 
receptors (FcRI and FcRIII) and more inhibitory receptors (FcRIIb).   
5.3 Estrogen receptors and vascular inflammation 
Studies in ERǂ- and ERǃ-deficient mice and in rats treated with pharmacologic antagonists 
of ERs have provided evidence that both ER subtypes contribute to the vasoprotective 
effects of E2 in the setting of acute injury. (Mori et al, 2000; Brouchet et al, 2001; Karas et al, 
1999; Geraldes et al, 2003; Xing et al, 2007). The ER subtypes contribute to vasoprotection in 
a cell-specific manner. In porcine endothelial and vascular smooth muscle cells, E2 acts 
through inhibition of PDGF-BB-induced p38 and p42/44 mitogen-activated protein kinase 
(MAPK) phosphorylation to stimulate migration and proliferation. (Geraldes et al, 2003)  
Down-regulation of ERǃ, but not ERǂ, prevented the effects of E2 on smooth muscle cell 
migration and proliferation. In contrast, in porcine endothelial cells, down-regulation of 
ERǂ prevented E2-induced p38 and p42/44 MAPK activation, while down-regulation of 
ERǃ had no effect. 
Administration of the ERǃ selective agonist DPN has been shown to result in dose-
dependednt attenuation of neointima formation induced by injury of the mouse femoral 
artery. (Krom et al, 2007)  The ERǂ selective agonist PPT prevented neointima formation at 
low but not high concentrations in this study. In a subsequent study, MPP, an ERǂ selective 
antagonist, blocked the inhibitory effect of PPT on neointima formation, but did not block the 
effects of E2 or DPN. (Harrington et al, 2003) This suggests that E2 acts through a selective ERǃ 
pathway to attenuate neointima formation following restenosis in this mouse model. 
The TNF-ǂ-stimulated vascular smooth muscle cell has been used as an in-vitro model of 
the vascular injury response in order to examine cellular/molecular mechanisms of E2-
induced vasoprotection. (Xing et al, 2007)  E2 has been shown to attenuate TNF-ǂ induced 
expression of pro-inflammatory mediators in rat aortic smooth muscle cells through ERǃ. 
(Xing et al, 2007)  In this model, DPN reduced TNF-ǂ-induced expression of the neutrophil 
cytokine CINC-2ǃ in a dose-dependent fashion, while PPT had no effect. The non-selective 
ER antagonist ICI-182,780 blocked the anti-inflammatory effects of both DPN and E2. 
Furthermore, both DPN and E2 reduced neutrophil chemotactic activity in TNF-ǂ-treated 
rat aortic SMCs.  
5.4 The role of aging in loss of estrogen-induced vasoprotection 
In order to reconcile laboratory findings that E2 provides vascular protection with clinical 
trial results indicating harmful effects of E2 on the cardiovascular system, studies have been 
done in models comparing young versus aged animals. Results from one study showed 
opposing effects of E2 based on age: E2 increased neointima formation in balloon-injured 
carotid arteries of aged (+75%) versus young (10-12 weeks; -40%) ovariectomized rats. 
(Miller et al, 2007)  The attenuating effect of E2 on inflammatory mediator expression and 
neutrophil and monocyte infiltration was lost in the injured arteries of aged rats. ERǂ and 
ERǃ expression was similar in both the young and aged animals. This laboratory evidence 
was the first of its kind to show that E2 exacerbates the vascular response to injury in aged 
animals. This seminal finding indicates that the protective effect of E2 is impaired following 
long periods of hormone deprivation, supporting the timing hypothesis. (Pinna et al, 2008)  
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The potential role of age-related alterations in ER signaling in these processes remains 
poorly understood and warrants further study. 
6. Reproductive aging, sex hormones, and women’s health 
Reproductive aging is a function of decreased production of sex hormones by the ovaries. 
As a woman enters her fifth decade of life, depletion of remaining ovarian follicles occurs. 
Estrogen production by the ovaries begins to decrease, and women experience progressive 
loss of menstrual cyclicity. When total depletion of follicles occurs, menses cease, and the 
woman enters menopause, defined as the absence of menses for a 12-month period. The 
average age of menopause in the United States is 51 years. (Speroff and Fritz, 2005)   Due to 
increasing lifespan, women can now expect to spend a significant portion of their lives in the 
postmenopausal state. This prolonged hypoestrogenism may have important consequences 
for quality of life, as well as various other health parameters, including cardiovascular 
function, bone health, and cognitive function.  
6.1 Age- and sex-specific trends 
CHD is rare in premenopausal women, but the incidence of myocardial infarction rises 
dramatically after menopause. Furthermore, women with premature ovarian failure or early 
natural menopause (≤ 44 years) have an associated increase in the risk of CVD. (Hu et al, 
1999) (Mondul et al 2005) These observations led to the belief that menopause itself is a risk 
factor for CHD. However, the relationship between menopause, age and CHD is complex 
and it is not clear that menopause per se is a risk factor for CHD. It is important to recognize 
that women who develop CHD after menopause have more CHD risk factors (dyslipidemia, 
family history, hypertension, tobacco use, and diabetes mellitus) compared to 
postmenopausal women who remain free of disease. Currently available data from 
randomized controlled trials, e.g., WHI and HERS, do not indicate that HRT is useful in the 
primary or secondary prevention of CHD. However, a growing body of evidence suggests 
that initiation of treatment with different HRT preparations in the perimenopausal period 
may have beneficial effects on the vasculature that may delay the progression of CVD and 
prevent ischemic events.  
6.2 Types and routes of administration of postmenopausal estrogen replacement 
therapy 
ERT is only indicated for the treatment of moderate to severe menopausal symptoms, 
specifically vasomotor symptoms (eg. hot flushes). Contraindications to ERT include known 
CHD, breast cancer, a previous venous thromboembolic event or stroke, active liver disease, 
or high risk for these conditions. ERT should be initiated as close to the time of menopause 
as possible, typically beginning in the late forties to early fifties. Initiation of therapy beyond 
age 59 is controversial due to increased risk of CHD events. Most physicians now agree that 
the benefit of estrogen treatment in healthy, early menopausal women, using the lowest 
dose and shortest duration of therapy, outweigh the risks of treatment. 
Systemic ERT can be given orally or non-orally in the form of transdermal patches and 
topical creams, gels, and mists.  Estrogen can also be given vaginally via tablets, topical 
formulations and vaginal rings. However, vaginal therapy is only indicated for the 
treatment of vaginal atrophy and not for systemic/vasomotor symptoms. Assuming that 
equivalent doses of replacement estrogen are given, the different routes of administration 
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are equivalent in ameliorating menopausal symptoms. Among the oral estrogens, E2 is 
considered to be the most potent estrogen and estrone is reported to be 50-70% less active. 
Estriol is the least potent of the three estrogens, with a potency one-tenth that of E2. 
While both oral and transdermal estrogens are absorbed systemically, oral estrogens are 
unique in that they undergo the “first-pass effect” in the liver. Intestinal absorption of 
estrogens leads to high concentrations of hormone in the portal vein, stimulating hepatic 
production of thyroxine-binding globulin, corticosteroid-binding globulin, SHBG, 
triglycerides, HDL, triglycerides, and clotting factors. Transdermal administration of 
estrogen does not have this effect and there is no resulting increased hepatic production of 
the above proteins.  
Multiple oral estrogen preparations are available, including CEE, E2, esterified estrogen, 
and conjugated synthetic estrogens. (Table 1)  
 
Estrogen Replacement Therapy 
Drug Company Dose Company Drug Dose 
Oral Therapy Transdermal Therapy 
Estradiol Estradiol 
Estrace Warner 
Chilcot 
0.5, 1, 2 mg 
Patches 
Gynodiol Firlding 0.5, 1, 1.5, 2 mg Alora Watson 0.025, 0.05, 
0.075, 0.1 
mg/d 
Conjugated equine estrogens 
Climara Berlax 0.025, 0.05, 
0.06, 0.075, 0.1 
mg/d 
Premarin Wyeth-Ayerst 0.3, 0.45, 0.625, 
0.9, 1.25 mg 
Esclim Women First 0.025, 0.0375, 
0.05, 0.075, 0.1 
mg/d 
Esterified Estrogens Estraderm Novartis 0.05, 0.1 mg/d 
Menest Monarch 0.3, 0.625, 1.25, 
2.5 mg 
Vivelle Novartis 0.025, 0.0375, 
0.05, 0.075, 0.1 
mg/d 
Ogen Pharmacia 0.75, 1.5, 3 mg Menostar Bayer 0.014 mg/d 
Ortho-Est 
Women First 
Healthcase 
0.5, 1.5, mg Gel 
Conjugated synthetic estrogens EstroGel Solvay 0.75 mg/pump 
Cenestin Elan 
0.3, 0.45, 0.625, 
0.9, 1.25 mg 
Emulsions 
Enjuvia Elan 0.625, 1.25 mg Estrasorb Novavox 
0.025 
mg/pouch 
Vaginal Therapy Divigel Upsher-Smith 
0.25, 0.5, 1 
mg/pouch 
Estradiol Elestrin Kenwood 0.52 mg/pump 
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Rings Spray 
Estring Pharmacia 0.0075 mg/day
EvaMist KV 
pharmaceutical 
1.5 mg/spray 
Femring 
Warner-
Chilcott 
0.05 mg/day    
Tablet    
Vagifem Novo Nordisk 0.025 mg/tablet    
Cream    
Estradiol    
Estrace 
Warner-
Chilcot 
0.1 mg/gram    
Conjugated equine estrogen    
Premarin Wyeth-Ayerst 0.625 mg/gram    
Table 1. Available Estrogen Formulations (Modified from Martin and Barbieri, 2011) 
CEE is one of the most commonly used preparations and, derived from mare urine, is 
composed of up to 10 different estrogenic compounds, predominantly the sodium 
sulfated conjungates of estrone. (Lyman GW 1982) The metabolism of CEE is a complex 
and still poorly understood process which occurs in the liver. After oral ingestion of CEEs, 
the compounds are rapidly absorbed by the gastrointestinal tract, then may become 
conjugated by hepatocytes or excreted in the feces. (Pan CC, 1985)  Following oral intake 
of CEEs, mean serum estrone levels (152 pg/mL) are far higher than estradiol levels (31 
pg/mL). (Powers MS et al 1985) However, the estrone component is largely inactive 
because it is albumin-bound. The clinical response to CEE is hypothesized to be mediated 
through a mechanism involving conversion of circulating, bound estrone to E2 in the 
liver. (Barnes RB et al 1987) 
E2 is another commonly prescribed oral form of postmenopausal ERT. Native E2 is poorly 
absorbed; therefore it is manufactured in micronized, sulfated, and esterified forms to 
improve absorption. (Krantz JC et al 1958)  Similar to metabolism of CEE, the majority of E2 
is converted to estrone. However, following oral administration of E2, mean circulating 
levels of estrone (200 pg/mL) and E2 (50 pg/mL) are higher compared to serum levels 
following ingestion of CEE when equivalent doses are given. (Lobo RA and Cassidenti DL 
1992)  E2 also induces hepatic production of proteins, but this effect is much less than that of 
CEEs. (Maschak CA et al 1982). 
Esterified estrogens result in serum E2 and estrone levels similar to those seen with CEEs. 
Synthetic conjugated estrogens are derived from plant sources. They are similar but not 
identical to CEEs and contain fewer molecular forms of estrogen. (Lobo et al, 2000) 
6.3 Types and routes of administration of progesterone replacement therapy 
Progesterone is indicated in addition to estrogen as part of a HRT regimen in 
postmenopausal women with an intact uterus (who have not undergone hysterectomy). 
Progesterone opposes the effects of estrogen on the endometrial lining and prevents 
development of endometrial hyperplasia and malignancy which occur in women treated 
with unopposed estrogen. Both natural and synthetic progestins are available. (Table 2) 
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Progesterone  Formulations 
Generic Name Brand Name Company Dose 
Oral Therapy 
Micronized Progesterone Prometrium Abbott 100, 200 mg 
Medroxyprogesterone Acetate Provera Pfizer 2.5, 5, 10 mg 
Norethindrone acetate Aygestin Teva 
Pharmaceuticals 
2.5, 5, 10 mg 
Vaginal Therapy 
Progesterone Cream Crinone Columbia 
Laboratories 
90 mg/applicator 
Progesterone Gel Prochieve Columbia 
Laboratories 
90 mg/applicator 
Intrauterine Device (IUD) 
Levonorgestrel IUD Mirena Bayer 52 mg/5 yrs 
Combination Estrogen-Progesterone Formulations 
Oral Therapy 
CEE/medroxyprogesterone Prempro Wyeth 0.3/1.5, 0.45/1.5, 
0.625/2.5, 0.625/5 mg 
Estradiol/norgestimate Prefest Duramed 1/0.9 mg 
Estradiol/norethindonr 
acetate 
Activella Novo Nordisk 1/0.5 mg 
Ethinyl 
estradiol/norethindrone 
FemHRT Warner-Chilcot 5 mcg/1mg 
Estradiol/drosperinone Angeliq Berlex 1/0.5 mg 
Transdermal Patches 
Estradiol/norethindrone Combi-Patch Novartis 0.05/0.14, 0.05/0.25 mg 
Estradiol/levonorgestrel Climara Pro Berlex 0.045/0.015 mg 
Table 2. Available Progesterone Preparations. (Modified from Martin and Barbieri, 2011) 
Micronized progesterone is the major natural progesterone available, and while it has been 
less well studied than MPA, it appears to be similar in efficacy and is widely prescribed. 
Synthetic progestins, including MPA, norgestrel, and norethindrone acetate, appear to 
increase hepatic lipase activity and attenuate the beneficial effects of estrogen on HDL levels 
(Stevenson 2009), while natural progesterone appears to have no adverse effect on HDL. 
MPA also opposes the NO-dependent vasodilator effect of E2, while natural progesterone 
was found to have no effect. (Williams AK et al 1994)  
7. Clinical research in hormone replacement therapy 
7.1 Observational studies 
The slope of the age-related rise in incidence of CVD in women increases in the post-
menopausal period, suggesting that withdrawal of ovarian hormones, particularly E2, has 
an adverse effect on cardiovascular health. (Lloyd-Jones et al, 2010)  This increase is thought 
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to be a consequence of the loss of the multiple protective effects of E2 on the vascular 
system. Multiple observational studies have suggested that HRT may protect against CVD 
in postmenopausal women. In a meta-analysis of 16 prospective observational trials, the 
relative risk of CVD for postmenopausal women who ever used any form of estrogen vs. 
those who had never used estrogen was 0.70 (95% CI, 0.63-0.77). (Grodstein et al, 1995)   The 
relative risk in current users, calculated from 6 prospective studies, was even more 
impressive at 0.55 (95% CI, 0.44-0.70). In the Nurses' Health Study, which followed more 
than 70,000 postmenopausal women for 20 years, the risk for major coronary events was 
lower among current users of HRT compared with never-users (multi-variate adjusted 
relative risk, 0.61 [95% CI, 0.52-0.71]). (Grodstein et al, 2000)  Buoyed by observational 
studies suggesting that HRT, including various E2 preparations with or without a progestin 
(most commonly a synthetic one), reduced CVD risk by ~50%. (Psaty et al, 1994)  HRT use 
increased dramatically during the 2 decades prior to the publication of the WHI. It is 
estimated that annual hormone therapy prescriptions increased from 58 million in 1995 to 90 
million in 1999, representing ~15 million women per year. (Hersh et al, 2004) This rate 
remained stable until 2002, but after the publication of WHI and other randomized 
controlled trials that showed no benefit of HRT, fell sharply by 66% in a single year. Many of 
the studies that prompted the upswing in postmenopausal HRT suffered from the 
limitations of discordance of the two treatment groups: women who take HRT are on 
average better educated, have higher incomes and better access to health care and are 
healthier even before starting therapy. (Barrett-Connor et al, 1989; Matthews et al, 1996)   In 
a meta-analysis that adjusted for socioeconomic status and other risk factors, HRT was not 
associated with CVD risk reduction. (Humphrey et al, 2002) 
7.2 Clinical trials 
Publication of the estrogen plus progestin clinical trial component of the Women’s Health 
Initiative (WHI) (Rossouw et al., 2002; Manson et al., 2003) initially sounded a death knell 
for hormone use in post-menopausal women. This placebo-controlled trial of HRT (CEE 
0.625 mg/day plus MPA 2.5 mg/day) in 16,608 post-menopausal women found significant 
increases in the risk of CHD, stroke, venous thromboembolism and invasive breast cancer in 
the HRT group. The reductions in colorectal cancer and hip fracture seen with HRT did not 
balance these increased CVD and cancer risks, and publication of the WHI results 
stimulated consensus panels to recommend against the use of HRT for chronic disease 
prevention in post-menopausal women (Mosca et al., 2004). Based on the widely publicized 
findings of harm in the estrogen plus progestin (E+P) trial of the WHI and a major 
secondary prevention study that used the same hormone regimen, the Heart and 
Estrogen/Progestin Replacement Study (HERS) (Hulley et al., 1998; Grady et al., 2002), 
prescribing of HRT fell drastically. (Hersh et al., 2004)  Transdermal hormone preparations 
were less affected, and transvaginal and low-dose preparations gained somewhat, reflecting 
caution in the use of the full-dose oral regimens that had been used in WHI and HERS. 
Attempts to explain the unanticipated deleterious effects of HRT gave consideration to 
whether the formulation, dose and route of administration of HRT might play a role (Dubey 
et al., 2004; Turgeon et al., 2004; Phillips & Langer, 2005). In particular, the progestin MPA 
was identified as having potential deleterious effects on the vasculature. Pre-clinical studies 
had shown that MPA negates the vasoprotective and anti-inflammatory effects of E2 in the 
setting of acute vascular injury (Levine et al., 1996; Oparil et al., 1997; Xing et al., 2004; Miller 
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et al., 2004) and in vitro studies found that MPA signals differently from native 
progesterone in endothelial cells (Simoncini et al., 2004). The surprising outcomes of the 
estrogen-alone (EA) component of WHI (WHI SC, 2004) added further evidence that MPA 
might be a problem and that unopposed estrogen benefits younger post-menopausal 
women. This trial, which was stopped early, showed no significant effect of unopposed CEE 
on the primary CHD outcome and a surprising tendency for benefit in the primary safety 
(invasive breast cancer) outcome. 
7.3 The timing hypothesis 
The advanced age (63 years in WHI, 67 years in HERS) and long period of hormone 
deprivation prior to starting HRT may account for deleterious outcomes of hormone 
treatment in WHI and HERS. Based on a review of pre-clinical studies, as well as 
observational studies and clinical trials in women, including those with intermediate end-
points and CVD outcomes, the “timing hypothesis” was developed (Phillips & Langer, 
2005). The timing hypothesis states that the effects of HRT on the vasculature are dependent 
on the time of initiation of treatment. The timing hypothesis predicts that HRT initiated at 
the time of or prior to menopause should produce a decrease in CHD over time, while HRT 
begun years after menopause should produce an increase in CHD events shortly after 
therapy is begun, followed by later benefit. This hypothesis attributes the complex CHD 
responses to HRT in human trials to a combination of early erosion/rupture of ‘vulnerable’ 
coronary plaque, which is made worse by HRT; long-term reduction in plaque formation, 
which is improved by HRT; and modulation of the vasoprotective actions of estrogens by 
systemic progestins.  
Indirect support for the timing hypothesis has come from the report of final results from the 
EA trial in WHI, which included detailed analyses of primary and secondary coronary 
outcomes and subgroup analyses of participants by age and years since hysterectomy with 
no menopausal hormone therapy (Hsia J, et al). During the active intervention period, 201 
coronary events were confirmed among women assigned to CEE compared with 217 events 
among women assigned to placebo (HR=0.95%; 95% CI 0.79-1.16). Among women aged 50-
59 years at baseline, the HR for the primary outcome (nonfatal myocardial infarction or 
coronary death) was 0.63 (95% CI 0.36-1.08). In that younger age group, coronary 
revascularization was less frequent among women assigned to CEE (HR=0.55; 95% CI 0.35-
0.86), as were several composite outcomes. Further analyses of the E+P arm of the WHI 
demonstrated a non-significant trend towards cardioprotection in women who began HRT 
less than 10 years after menopause (HR = 0.89; 95% CI 0.5-1.5), while women who initiated 
HRT more than 20 years after menopause had a significantly elevated risk of coronary 
events (HR = 1.71; 95% CI, 1.1-2.5). (Manson et al, 2003)  When the EA and E+P arms from 
the WHI were combined, a similar trend was seen. (Rossouw et al, 2007) 
Another consideration in the relationship between HRT and CVD risk is the duration of 
HRT. A recent post-hoc analysis of the E+P trial in WHI showed that in women less than 10 
years since menopause, HRT resulted in a slightly lower event-free survival rate during the 
first 5 years of therapy compared to placebo; however, at 6 years, the two curves crossed 
each other and showed a non-significant trend towards a higher rate of event-free survival 
in the group using HRT. (Toh et al, 2010)  Further analysis of women less than 10 years since 
menopause in the WHI E+P arm showed an increased risk in the first 2 years of HRT, 
followed by a decreased risk in the next 2 years, and an overall risk reduction over 8 years. 
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(Toh et al, 2010). Similar results were seen in the EA arm of the WHI, with a significant 
decrease in CHD risk after 6 years of CEE alone compared to placebo. (Harman et al, 2011) 
Among women in the EA arm of the WHI followed up over 10.7 years, there was no 
difference in CHD risk in those using CEE for a median of 5.9 years compared to placebo at 
the end of the active treatment period, or overall. (LaCroix et al, 2011)  In the post-
intervention follow-up period, the annualized rate for CHD in the EA arm was 0.64% 
compared to 0.67% in the placebo group (HR 0.97, 95% CI, 0.75-1.25). Health outcomes, 
including CHD, were more favorable for younger women compared to older women 
(P=0.05 for interaction). These findings support the current clinical recommendations to 
treat postmenopausal women with HRT for the “shortest possible duration” and may lead 
to more individualized management.  
The WHI was limited by use of only one type of ERT (CEE), by inclusion of women who 
initiated HRT late after many years of ovarian hormone deprivation, and by exclusion of 
women who were experiencing menopausal symptoms. Ongoing clinical trials are 
addressing these deficiencies by examining the timing hypothesis in perimenopausal 
women. The Kronos Early Estrogen Prevention Study (KEEPS) is a prospective, 
randomized, double-blind study of 900 healthy perimenopausalwomen aged 45-54 with 
menopausal symptoms. (Harman et al., 2005)  The main hypotheses are 1) HRT initiated 
early in menopause (before development of atherosclerotic lesions) will prevent progression 
of atherosclerotic lesions, and 2) both oral CEE and transdermal E2 will be similarly 
efficacious.  Participants were randomized to oral CEE and a placebo patch, oral placebo 
and a transdermal patch containing E2, or placebo in both pill and patch. The primary 
endpoints of KEEPS are carotid intimal medial thickness by ultrasound and the progression 
of coronary calcium by electron beam tomography, surrogates for CVD. Another ongoing 
prospective, randomized, controlled trial, the Early versus Late Intervention Trial with 
Estradiol (ELITE) randomized 643 women who were less than 6 years or more than 10 years 
since menopause to receive oral E2 versus placebo. (clinicaltrials.gov NCT00114517; Hodis 
and Mack, 2011)  The primary endpoint is rate of change of carotid artery intima-media 
thickness. These two prospective studies will provide much-needed information regarding 
the timing hypothesis and use of HRT in reducing CVD risk. 
7.4 Oral versus transdermal HRT 
To date, few studies have examined the difference in CHD outcomes between 
postmenopausal women treated with oral versus transdermal therapy. The one existing trial 
in the literature suggests no difference in CHD outcomes with regard to route. (Clarke SC 
2002)  This study examined transdermal E2 with or without transdermal norethindrone 
acetate, and found similar CHD outcomes to the WHI.  The literature indicates that dose 
may be more important than route. 
8. Conclusions 
Importantly, cellular and molecular studies are urgently needed to elucidate the differential 
effects of HRT and its components on young, healthy arteries and on older, diseased 
arteries. Emerging evidence suggests that HRT administered to young healthy women has 
anti-inflammatory and vasodilator effects that tend to lower blood pressure and slow the 
progression of atherosclerotic lesions, while the same HRT preparation administered to 
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older women, particularly those with established vascular disease, has a proinflammatory 
effect, perhaps leading to atherosclerotic plaque instability and neovascularization (Störk et 
al., 2004; Mendelsohn & Karas, 2005). The mechanisms of these altered vascular responses 
are not fully understood, but may relate to age-related deterioration in ER expression and 
signaling. Recent studies of the effects of HRT on blood pressure and vascular function 
support the age-dependence of the action of HRT on the vasculature. Beneficial effects of 
HRT appear to be realized only in younger, perimenopausal women in whom hormone 
response systems remain intact. However, further study of the timing, dose, duration, and 
route of administration of HRT in postmenopausal women may be informative. 
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